An NIS Registry for the Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer (Stage IIIB/IV Non-small Cell Lung Cancer)
18 Years
N/A
Both
Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Trial Information
An NIS Registry for the Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer (Stage IIIB/IV Non-small Cell Lung Cancer)
An NIS Registry for the Epidemiological and Scientific evaluation of EGFR mutation status in
patients with newly diagnosed locally advanced or metastatic NSCLC (stage IIIB/IV non-small
cell lung cancer)
Inclusion Criteria
Histologically confirmed locally advanced or metastatic NSCLC (stage IIIB/IV). Mixed
histology of small cell and non-small cell lung cancer
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
The primary objective of the study is to collect epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity and to correlate EGFR mutation status with clinico-pathological characteristics
Outcome Time Frame:
Days 1-10
Safety Issue:
No
Principal Investigator
Prof. Dr. H. Brasch
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca Germany
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
NIS-ODE-DUM-2009/1
NCT ID:
NCT00997230
Start Date:
September 2009
Completion Date:
October 2012
Related Keywords:
- Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
- EGFR mutation ,newly diagnosed NSCLC, locally advanced or metastatic NSCLC
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
